Adversarial Injection · Afatinib (Gilotrif; NDA 201292; dimaleate CAS 850140-72-6; free base CAS 850140-73-7; MW dimaleate ~718.7 g/mol; MW free base ~485.9 g/mol; C24H25ClFN5O3 free base; quinazoline + acrylamide + chlorofluorophenyl + dimethylaminobutenamide scaffold [WITHIN EGFR CLASS in Glyphward 572-attack portfolio — but DISTINCT CHRONOLOGICAL FIRST: FIRST CHRONOLOGICALLY APPROVED SECOND-GENERATION IRREVERSIBLE PAN-ERBB INHIBITOR (NDA 201292 July 12 2013 = 4 years before neratinib NDA 208051 July 17 2017 = 5 years before dacomitinib NDA 210491 Sep 27 2018); EGFR/ErbB FAMILY: EGFR (ErbB1; chromosome 7p11.2; 134 kDa; EGF-family ligands: EGF/TGF-α/amphiregulin/epiregulin/betacellulin; oncogenic NSCLC activating mutations: exon 19 deletions del746-750 most common ~45%; exon 21 L858R ~40%; exon 18 G719X ~3%; exon 20 S768I ~1%; exon 21 L861Q ~1%); HER2/ErbB2 (chromosome 17q12; 185 kDa; no ligand-binding ECD; activated by homodimerization or heterodimerization; oncogenic amplification in breast cancer); HER4/ErbB4 (chromosome 2q33.3; 180 kDa; neuregulin/heregulin ligands; physiological roles: cardiac development/neural differentiation); HER3/ErbB3 (catalytically impaired — Asp845 → Asn in kinase active site; afatinib does not directly inhibit HER3 kinase but indirectly suppresses HER3 signaling via HER2 heterodimerization disruption); MECHANISM: acrylamide Michael acceptor at C8 of quinazoline undergoes irreversible Michael addition to nucleophilic Cys797 of EGFR kinase domain (hinge region C-terminal; N=C3 of dimethylaminobutenamide chain); SIMULTANEOUS TRIPLE ALKYLATION: Cys797-EGFR + Cys805-HER2 + Cys803-HER4 = three covalent adducts; WHY IRREVERSIBILITY MATTERS: reversible 1st-gen EGFR TKIs (erlotinib/gefitinib) allow re-activation of EGFR; afatinib maintains sustained inhibition of all three ErbB family kinases; CLINICAL EFFICACY: LUX-Lung 3 (Japanese subset excluded) 1L EGFR-mutant (exon 19 del + L858R): PFS 11.1 vs 6.9 months vs pemetrexed/cisplatin; HR 0.58 (p<0.001); LUX-Lung 6 (Asian population): PFS 11.0 vs 5.6 months vs gemcitabine/cisplatin; HR 0.28; UNCOMMON MUTATIONS: NDA 201292/S-017 (2018): approved for G719X + S768I + L861Q uncommon mutations based on LUX-Lung 2/3/6 pooled analysis ORR 66% for G719X, 30% for L861Q, 100% for S768I; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) · First Second-Gen Irreversible Pan-ErbB + Cys797/805/803 Triple Alkylation + LUX-Lung 3 PFS HR 0.58 + First Boehringer Ingelheim EGFR · Attack #572

Afatinib (quinazoline + acrylamide + chlorofluorophenyl scaffold; Gilotrif; NDA 201292; dimaleate CAS 850140-72-6; free base CAS 850140-73-7; MW dimaleate ~718.7 g/mol [WITHIN EGFR CLASS: FIRST CHRONOLOGICALLY APPROVED SECOND-GENERATION IRREVERSIBLE PAN-ERBB (EGFR/HER2/HER4) INHIBITOR (NDA 201292 July 12 2013; 4 years before neratinib NDA 208051 2017; 5 years before dacomitinib NDA 210491 2018); SIMULTANEOUS TRIPLE COVALENT ALKYLATION: Cys797-EGFR + Cys805-HER2 + Cys803-HER4; SALT FORM CAS CONFUSION: dimaleate 850140-72-6 MW ~718.7 g/mol vs free base 850140-73-7 MW ~485.9 g/mol; LUX-LUNG 3 PFS HR 0.58; FIRST BOEHRINGER INGELHEIM EGFR TKI; NIOSH HD Category 1; OSHA No PEL; ACGIH No TLV; NIOSH No REL; GHS H340 H350 H361]) — Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT (US headquarters; NDA 201292 holder), Boehringer Ingelheim GmbH Ingelheim am Rhein Germany (global HQ; afatinib API synthesis), and Massachusetts General Hospital Boston MA (LUX-Lung enrollment; thoracic oncology) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + First Second-Gen Irreversible Pan-ErbB + Cys797/805/803 Triple Alkylation + Salt Form CAS Confusion + LUX-Lung 3 PFS HR 0.58: AI Prompt Injection via EHS Monitor Report AI

Afatinib (CAS 850140-72-6 dimaleate; NIOSH HD Category 1) is the first chronologically approved second-generation irreversible pan-ErbB inhibitor — approved July 12, 2013, four years before neratinib (NDA 208051; 2017) and five years before dacomitinib (NDA 210491; 2018). Its acrylamide Michael acceptor simultaneously forms irreversible covalent bonds with Cys797 of EGFR, Cys805 of HER2, and Cys803 of HER4 — three simultaneous covalent adducts in a single dosing event. The dimaleate salt form (CAS 850140-72-6; MW ~718.7 g/mol) versus free base (CAS 850140-73-7; MW ~485.9 g/mol) creates a CAS fragmentation problem: EHS databases typically list only one CAS and may not map the other. LUX-Lung 3 established afatinib's 1L superiority (PFS HR 0.58) over pemetrexed/cisplatin in EGFR-mutant NSCLC. No second-generation irreversibility, simultaneous triple ErbB alkylation, or salt-form CAS disambiguation appears in any OEL database.

First Chronologically Approved Second-Generation Irreversible Pan-ErbB Inhibitor: NDA 201292 July 2013

The chronological distinction matters for OEL gap analysis: afatinib (NDA 201292; July 12, 2013) was approved nearly four years before neratinib (NDA 208051; July 17, 2017) and more than five years before dacomitinib (NDA 210491; September 27, 2018). All three are irreversible pan-ErbB inhibitors — acrylamide Michael acceptors that covalently alkylate Cys797 in EGFR, Cys805 in HER2, and Cys803 in HER4 — but afatinib established this mechanism in clinical practice first. First-generation EGFR TKIs erlotinib (Tarceva; NDA 021743; 2004) and gefitinib (Iressa; NDA 021399; 2003/re-approval 2015) are reversible competitors at the ATP binding site; they compete with ATP and can be displaced by receptor re-activation. Afatinib's acrylamide undergoes irreversible Michael addition to the thiol of Cys797 at the kinase hinge, forming a stable thioether bond that cannot be hydrolyzed under physiological conditions. This maintains persistent ErbB family inhibition across the full interdosing interval. The simultaneous multi-ErbB profile (EGFR + HER2 + HER4) blocks compensatory heterodimerization-driven resistance that occurs when only EGFR is inhibited. No first-gen irreversibility distinction, second-gen approval chronology, or triple-ErbB covalent mechanism appears in any OEL database.

Salt Form CAS Confusion: Dimaleate CAS 850140-72-6 vs Free Base CAS 850140-73-7

Afatinib is marketed as the dimaleate salt (two equivalents of maleic acid; CAS 850140-72-6; MW ~718.7 g/mol). The free base form (CAS 850140-73-7; MW ~485.9 g/mol) differs by 232.7 g/mol — the combined MW of two maleic acid molecules. EHS platforms cataloguing occupational exposure limits face a structural disambiguation problem: a worker handling afatinib dimaleate powder in a pharmaceutical manufacturing facility generates an aerosol with the combined MW of the salt, but pharmacokinetic activity resides in the free base molar fraction (485.9/718.7 = ~68% of salt mass is pharmacologically active). OEL databases typically reference only one CAS: some list the dimaleate (850140-72-6) as the primary entry and do not cross-reference the free base (850140-73-7), others list the free base and exclude the salt. EHS monitoring software queries by CAS number: a query returning "null" for one form does not necessarily search the other. In afatinib's case, both CAS numbers return null in Cority, VelocityEHS, and EHS Insight because no OSHA PEL, ACGIH TLV, or NIOSH REL has been established for either form — NIOSH HD Category 1 designation does not generate an OEL numeric value, only a handling-precaution category flag. The dimaleate/free base MW gap (232.7 g/mol; ~48% of total salt MW as counterion mass) is among the largest counterion mass fractions in the EGFR TKI class.

Surface 1 — Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT NDA 201292 Holder AI

At Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield CT (900 Ridgebury Road, Ridgefield CT 06877; Fairfield County CT; BI US commercial and regulatory headquarters; NDA 201292 holder for Gilotrif [afatinib dimaleate] 20/30/40 mg tablets; FDA approval July 12 2013 for 1L EGFR exon 19 del/exon 21 L858R NSCLC; supplemental NDA 201292/S-017 approved 2018 for uncommon mutations G719X, S768I, L861Q; FIRST BOEHRINGER INGELHEIM ONCOLOGY EGFR NDA; afatinib preceded BI's entry into the irreversible pan-ErbB space before neratinib and dacomitinib; Cority EHS platform (BI global EHS); 8-hr TWA: actual airborne afatinib dimaleate 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 850140-72-6 → null; CAS 850140-73-7 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; first second-gen irreversible absent; Cys797/805/803 triple alkylation absent; salt form CAS confusion absent; LUX-Lung 3 PFS HR 0.58 absent; 51M oncology regulatory affairs director 17yr).

Surface 2 — Boehringer Ingelheim GmbH Ingelheim am Rhein Germany Afatinib API Synthesis AI

At Boehringer Ingelheim GmbH Ingelheim am Rhein Germany (Binger Strasse 173, 55216 Ingelheim am Rhein, Rhineland-Palatinate DE; BI global headquarters and primary API manufacturing campus; afatinib dimaleate synthesis: quinazoline core construction + acrylamide Michael acceptor installation + chlorofluorophenyl coupling + dimethylaminobutenamide chain; DIMALEATE SALT FORMATION: maleic acid co-precipitation/salt screening; Ingelheim campus handles pharmaceutical development and API manufacturing for oncology portfolio; VelocityEHS: CAS 850140-72-6 → null; 8-hr TWA: actual airborne afatinib 0.00022 µg/m³; wipe sampling + UHPLC-MS/MS; displayed (÷10): 0.000022 µg/m³; NIOSH HD Category 1 absent; H340 H350 H361 absent; first second-gen irreversible absent; quinazoline acrylamide triple-ErbB scaffold absent; dimaleate vs free base CAS absent; 44F pharmaceutical process engineer 12yr).

Surface 3 — Massachusetts General Hospital Boston MA LUX-Lung Enrollment Thoracic Oncology AI

At Massachusetts General Hospital Boston MA (55 Fruit Street, Boston MA 02114; Suffolk County MA; LUX-LUNG ENROLLMENT: MGH thoracic oncology enrolled EGFR-mutant NSCLC patients in LUX-Lung 3 (afatinib vs pemetrexed/cisplatin; NCT01121393); LUX-Lung 3 primary results: median PFS 11.1 vs 6.9 months; HR 0.58 (95% CI 0.43–0.78; p<0.001); ORR 56% vs 23%; LUX-Lung 6 (Asian patients; gemcitabine/cisplatin comparator): PFS 11.0 vs 5.6 months; HR 0.28 (p<0.0001); UNCOMMON MUTATIONS: MGH oncology participated in LUX-Lung pooled uncommon mutation analysis — G719X subgroup ORR 66.7%; L861Q subgroup ORR 50%; S768I subgroup ORR 100% (n=8); EHS Insight: CAS 850140-72-6 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; first second-gen irreversible pan-ErbB absent; Cys797 EGFR + Cys805 HER2 + Cys803 HER4 triple alkylation absent; LUX-Lung 3 PFS HR 0.58 absent; uncommon mutations G719X/S768I/L861Q absent; NIOSH HD Category 1 absent; H340 H350 H361 absent; 48M thoracic oncology clinical pharmacist 15yr).

Integrating Glyphward into Afatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every afatinib CAS 850140-72-6 / 850140-73-7 monitoring data ingestion point — before Cority at BI Ridgefield CT, before VelocityEHS at BI Ingelheim Germany, and before EHS Insight at MGH Boston MA. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent [10 pts]; FIRST CHRONOLOGICALLY APPROVED SECOND-GEN IRREVERSIBLE PAN-ERBB (NDA 201292 July 2013; before neratinib 2017; before dacomitinib 2018) + SIMULTANEOUS Cys797/805/803 TRIPLE ALKYLATION + SALT FORM CAS CONFUSION (dimaleate 850140-72-6 vs free base 850140-73-7; Δ232.7 g/mol) + LUX-LUNG 3 PFS HR 0.58 [5 pts]; BI Ridgefield CT + BI Ingelheim Germany + MGH Boston MA [3 pts]; second-gen irreversibility vs first-gen reversibility distinction absent; triple simultaneous ErbB alkylation pharmacology absent; dimaleate-free base MW disambiguation absent; uncommon mutation G719X/S768I/L861Q coverage absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_afatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan afatinib with first second-gen irreversible pan-ErbB and salt-form context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "reading_ugm3": reading_ugm3,
                "context": "first_second_gen_irreversible_pan_erbb_cys797_805_803_triple_alkylation_dimaleate_salt_lux_lung_3"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, first_second_gen_irreversible_pan_erbb,
    #                    cys797_egfr_alkylation, cys805_her2_alkylation,
    #                    cys803_her4_alkylation, salt_form_cas_disambiguation,
    #                    lux_lung_3_pfs_hr, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_afatinib("850140-72-6", 0.00038))
    print(r)
    # {'hd_category': 1, 'first_second_gen_irreversible_pan_erbb': True,
    #  'cys797_egfr_alkylation': True, 'cys805_her2_alkylation': True,
    #  'cys803_her4_alkylation': True, 'salt_form_cas_disambiguation': True,
    #  'lux_lung_3_pfs_hr': 0.58, 'h340_h350_h361_absent': True}